NASDAQ:NUVL

Nuvalent (NUVL) Stock Forecast, Price & News

$43.16

+0.54 (+1.27%)

(As of 02:55 PM ET)

Compare

Today's Range: $42.19
▼
$43.48
50-Day Range: $41.11
▼
$49.85
52-Week Range: $15.56
▼
$50.58

Volume: 304,116 shs
Average Volume: 280,274 shs
Market Capitalization: $2.46 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $48.60

Nuvalent MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 14.5% Upside
$48.60 Price Target
Short Interest: Bearish
10.04% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.60
Based on 3 Articles This Week
Insider Trading: Selling Shares
$1.05 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.12) to ($2.76) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

Medical Sector

799th out of 961 stocks

Pharmaceutical Preparations Industry

377th out of 449 stocks

3.3

Analyst's Opinion

Consensus Rating
Nuvalent has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $48.60, Nuvalent has a forecasted upside of 14.5% from its current price of $42.45.
Amount of Analyst Coverage
Nuvalent has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
10.04% of the float of Nuvalent has been sold short.
Short Interest Ratio / Days to Cover
Nuvalent has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.
Change versus previous month
Short interest in Nuvalent has recently decreased by 2.40%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Nuvalent does not currently pay a dividend.
Dividend Growth
Nuvalent does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NUVL.

1.9

News and Social Media Coverage

News Sentiment
Nuvalent has a news sentiment score of -0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Nuvalent this week, compared to 1 article on an average week.
Search Interest
3 people have searched for NUVL on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
MarketBeat Follows
1 people have added Nuvalent to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nuvalent insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,051,270.00 in company stock.
Percentage Held by Insiders
14.77% of the stock of Nuvalent is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
97.26% of the stock of Nuvalent is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Nuvalent are expected to decrease in the coming year, from ($2.12) to ($2.76) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Nuvalent is -22.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Nuvalent is -22.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Nuvalent has a P/B Ratio of 4.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Nuvalent (NASDAQ:NUVL) Stock

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase ½ clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is ongoing IND-enabling studies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

NUVL Price History

30 days | 90 days | 365 days | Advanced Chart

NUVL Stock News Headlines

September 18, 2023 | markets.businessinsider.com

Nuvalent (NUVL) Receives a Buy from Piper Sandler

September 18, 2023 | finance.yahoo.com

Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium

September 21, 2023 | UNKNOWN (Ad)

Out Of This World Stock Alerts!

There Is This One Lithium Stock That Has Our Full Attention! Sign Up And Learn More!

September 12, 2023 | americanbankingnews.com

Nuvalent's (NUVL) "Outperform" Rating Reaffirmed at Wedbush

September 10, 2023 | finance.yahoo.com

We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely

September 5, 2023 | finance.yahoo.com

Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors

August 31, 2023 | finance.yahoo.com

Nuvalent to Participate in Upcoming September Investor Conferences

August 10, 2023 | finanznachrichten.de

Nuvalent, Inc.: Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results

September 21, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

August 10, 2023 | finance.yahoo.com

Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results

August 8, 2023 | msn.com

SVB Leerink Initiates Coverage of Nuvalent Inc - (NUVL) with Market Perform Recommendation

August 8, 2023 | markets.businessinsider.com

Expert Ratings for Nuvalent

August 1, 2023 | finance.yahoo.com

Nuvalent to Participate in Upcoming August Investor Conferences

July 25, 2023 | msn.com

Guggenheim Initiates Coverage of Nuvalent Inc - (NUVL) with Buy Recommendation

July 21, 2023 | finance.yahoo.com

Recent Price Trend in Nuvalent, Inc. (NUVL) is Your Friend, Here's Why

July 6, 2023 | msn.com

Nuvalent Inc - (NUVL) Price Target Increased by 6.95% to 51.00

June 7, 2023 | finance.yahoo.com

Nuvalent, Inc. (NUVL) Is a Great Choice for 'Trend' Investors, Here's Why

May 25, 2023 | msn.com

Nuvalent: Good Medicine, But Futuristic Valuation

May 24, 2023 | finance.yahoo.com

Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit

May 12, 2023 | msn.com

Nuvalent: Q1 Earnings Insights

May 11, 2023 | finance.yahoo.com

Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results

April 19, 2023 | finance.yahoo.com

Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology Days

April 18, 2023 | finance.yahoo.com

Nuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023

April 5, 2023 | nasdaq.com

Nuvalent Breaks Below 200-Day Moving Average - Notable for NUVL

April 2, 2023 | finance.yahoo.com

Nuvalent (NASDAQ:NUVL) Is In A Strong Position To Grow Its Business

March 23, 2023 | finance.yahoo.com

Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)

March 17, 2023 | markets.businessinsider.com

BMO Capital Keeps Their Buy Rating on Nuvalent (NUVL)

See More Headlines

Receive NUVL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvalent and its competitors with MarketBeat's FREE daily newsletter.

NUVL Company Calendar

Last Earnings: 8/10/2023
Today: 9/21/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NUVL
CUSIP: N/A
CIK: 1861560
Web: www.nuvalent.com
Phone: 857-357-7000
Fax: N/A
Employees: 78
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $48.60
High Stock Price Forecast: $56.00
Low Stock Price Forecast: $42.00
Forecasted Upside/Downside: +13.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.85)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-81,850,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -25.59%
Return on Assets: -24.50%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 21.01
Quick Ratio: 21.01

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.59 per share
Price / Book: 4.47

Miscellaneous

Outstanding Shares: 57,030,000
Free Float: 48,602,000
Market Cap: $2.44 billion
Optionable: Not Optionable
Beta: 1.35

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. James R. Porter Ph.D. (Age 47)
CEO, Pres & Director
Comp: $998.02k

Prof. Matthew D. Shair Ph.D. (Age 54)
Founder, Head of Scientific Advisory Board & Director
Comp: $235k

Ms. Alex Balcom CPA (Age 38)
M.B.A., CFO & Treasurer
Comp: $654.22k

Dr. Christopher D. Turner M.D. (Age 54)
Chief Medical Officer
Comp: $714.26k

Dr. Benjamin Lane
Sr. VP of Technical Operations

Ms. Deborah Ann Miller J.D. (Age 47)
Ph.D., Chief Legal Officer & Sec.

Mr. Matthew Metivier
VP of HR

Ms. Darlene Noci (Age 46)
Chief Devel. Officer

Mr. Henry Pelish Ph.D.
Sr. VP of Drug Discovery

Mr. John Soglia Ph.D.
Sr. VP of Translational Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NUVL Stock - Frequently Asked Questions

Should I buy or sell Nuvalent stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nuvalent in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NUVL shares.
View NUVL analyst ratings or view top-rated stocks.
What is Nuvalent's stock price forecast for 2023?: 6 analysts have issued 12 month price targets for Nuvalent's stock. Their NUVL share price forecasts range from $42.00 to $56.00. On average, they expect the company's share price to reach $48.60 in the next twelve months. This suggests a possible upside of 13.5% from the stock's current price.
View analysts price targets for NUVL or view top-rated stocks among Wall Street analysts.
How have NUVL shares performed in 2023?: Nuvalent's stock was trading at $29.78 at the beginning of 2023. Since then, NUVL stock has increased by 43.8% and is now trading at $42.82.
View the best growth stocks for 2023 here.
When is Nuvalent's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our NUVL earnings forecast.
How were Nuvalent's earnings last quarter?: Nuvalent, Inc. (NASDAQ:NUVL) announced its earnings results on Thursday, August, 10th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.04.
What ETFs hold Nuvalent's stock?: ETFs with the largest weight of Nuvalent (NASDAQ:NUVL) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Invesco DWA SmallCap Momentum ETF (DWAS).

When did Nuvalent IPO?: (NUVL) raised $151 million in an IPO on Thursday, July 29th 2021. The company issued 8,900,000 shares at $16.00-$18.00 per share.
What is Nuvalent's stock symbol?: Nuvalent trades on the NASDAQ under the ticker symbol "NUVL."
Who are Nuvalent's major shareholders?: Nuvalent's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.22%), Perceptive Advisors LLC (3.86%), Driehaus Capital Management LLC (2.54%), State Street Corp (2.06%), Commodore Capital LP (2.02%) and Geode Capital Management LLC (0.93%). Insiders that own company stock include Christopher Durant Turner, Darlene Noci, Deborah Ann Miller and Matthew Shair.
View institutional ownership trends.
How do I buy shares of Nuvalent?: Shares of NUVL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Nuvalent's stock price today?: One share of NUVL stock can currently be purchased for approximately $42.82.
How much money does Nuvalent make?: Nuvalent (NASDAQ:NUVL) has a market capitalization of $2.44 billion. The company earns $-81,850,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis.
How can I contact Nuvalent?: The official website for the company is www.nuvalent.com. The company can be reached via phone at 857-357-7000 or via email at ir@nuvalent.com.

This page (NASDAQ:NUVL) was last updated on 9/21/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial